Contact MENU

Pipeline

We’re excited about the products we have in the pipeline and the impact they will have on patients.

Product Indication Preclin Phase One Phase Two Phase Three
KIO-101 (Eyedrop) Ocular Manifestations of Rheumatoid Arthritis
 
 
 
 
KIO-201 (Eyedrop) PRK Surgical Recovery
 
 
 
 
KIO-301 (Intravitreal) Retinitis Pigmentosa
 
 
 
 
KIO-102 (Oral) Autoimmune Diseases
 
 
 
 
These therapeutics are still in development and are not yet approved for commercial use.
NEWS
01.05.22

Kiora Pharmaceuticals to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference

SALT LAKE CITY, UT, Jan 05, 2022 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) will participate in the H.C. Wainwright Bioconnect Virtual Conference January 10-13, 2022. Brian M Strem, Ph.D., President...
Read more
Healthy Eyes Checkup
12.15.21

Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors

SALT LAKE CITY, UT, Dec 15, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced the appointment of David Hollander, MD, MBA, to its Board of Directors....
Read more
Healthy Eyes PR
12.14.21

Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease

SALT LAKE CITY, UT, Dec 14, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The...
Read more